{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:25:19Z","timestamp":1778736319364,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA237039"],"award-info":[{"award-number":["CA237039"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001384","name":"Samuel Waxman Cancer Research Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100001384","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myelodysplastic syndrome (MDS) is a heterogeneous myeloid malignancy characterized by blood cell morphological dysplasia, ineffective clonal hematopoiesis, and risk of transformation to secondary acute myeloid leukemia (sAML). A number of genetic abnormalities have been identified in MDS and sAML, but sensitive sequencing methods can detect these mutations in nearly all healthy individuals by 60 years of age. To discover novel cellular pathways that accelerate MDS and sAML, we performed a CRISPR\/Cas9 screen in the human MDS-L cell line. We report here that loss of the F-Box protein FBXO11, a component of the SCF ubiquitin ligase complex, confers cytokine independent growth to MDS-L cells, suggesting a tumor suppressor role for FBXO11 in myeloid malignancies. Putative FBXO11 substrates are enriched for proteins with functions in RNA metabolism and, of note, spliceosome mutations that are commonly found in MDS\/sAML are rare in patients with low FBXO11 expression. We also reveal that loss of FBXO11 leads to significant changes in transcriptional pathways influencing leukocyte proliferation, differentiation, and apoptosis. Last, we find that FBXO11 expression is reduced in patients with secondary AML. We conclude that loss of FBXO11 is a mechanism for disease transformation of MDS into AML, and may represent a future therapeutic target.<\/jats:p>","DOI":"10.1038\/s41408-020-00362-7","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T01:03:24Z","timestamp":1602032604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9994-8579","authenticated-orcid":false,"given":"Michael","family":"Schieber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Marinaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-5277","authenticated-orcid":false,"given":"Lyndsey C.","family":"Bolanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy D.","family":"Haffey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth D.","family":"Greis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel T.","family":"Starczynowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8182-8306","authenticated-orcid":false,"given":"John D.","family":"Crispino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"362_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrc.2016.112","volume":"17","author":"AS Sperling","year":"2017","unstructured":"Sperling, A. S., Gibson, C. J. & Ebert, B. L. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat. Rev. Cancer 17, 5\u201319 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"362_CR2","doi-asserted-by":"publisher","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","volume":"366","author":"S Jaiswal","year":"2019","unstructured":"Jaiswal, S. & Ebert, B. L. Clonal hematopoiesis in human aging and disease. Science 366, eaan4673 (2019).","journal-title":"Science"},{"key":"362_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12484","volume":"7","author":"AL Young","year":"2016","unstructured":"Young, A. L., Challen, G. A., Birmann, B. M. & Druley, T. E. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat. Commun. 7, 12484 (2016).","journal-title":"Nat. Commun."},{"key":"362_CR4","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/blood-2018-03-784116","volume":"132","author":"L Barreyro","year":"2018","unstructured":"Barreyro, L., Chlon, T. M. & Starczynowski, D. T. Chronic immune response dysregulation in MDS pathogenesis. Blood 132, 1553\u20131560 (2018).","journal-title":"Blood"},{"key":"362_CR5","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41586-018-0125-z","volume":"557","author":"M Meisel","year":"2018","unstructured":"Meisel, M. et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557, 580\u2013584 (2018).","journal-title":"Nature"},{"key":"362_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2141.1994.tb04904.x","volume":"87","author":"K Tohyama","year":"1994","unstructured":"Tohyama, K., Tsutani, H., Ueda, T., Nakamura, T. & Yoshida, Y. Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome. Br. J. Haematol. 87, 235\u2013242 (1994).","journal-title":"Br. J. Haematol."},{"key":"362_CR7","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/leu.2013.372","volume":"28","author":"G Rhyasen","year":"2014","unstructured":"Rhyasen, G. et al. An MDS xenograft model utilizing a patient-derived cell line. Leukemia 28, 1142\u20131145 (2014).","journal-title":"Leukemia"},{"key":"362_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ccr.2013.05.006","volume":"24","author":"GW Rhyasen","year":"2013","unstructured":"Rhyasen, G. W. et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 24, 90\u2013104 (2013).","journal-title":"Cancer Cell"},{"key":"362_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrm3582","volume":"14","author":"JR Skaar","year":"2013","unstructured":"Skaar, J. R., Pagan, J. K. & Pagano, M. Mechanisms and function of substrate recruitment by F-box proteins. Nat. Rev. Mol. Cell Biol. 14, 369\u2013381 (2013).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"362_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature10688","volume":"481","author":"S Duan","year":"2012","unstructured":"Duan, S. et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 481, 90\u201393 (2012).","journal-title":"Nature"},{"key":"362_CR11","doi-asserted-by":"crossref","first-page":"PR10","DOI":"10.1158\/1557-3265.HEMMAL17-PR10","volume":"23","author":"C Pighi","year":"2017","unstructured":"Pighi, C. et al. FBXO11 is recurrently mutated in Burkitt lymphoma and its inactivation accelerates lymphomagenesis in E\u03bc-myc mice. Clin. Cancer Res. 23, PR10 (2017).","journal-title":"Clin. Cancer Res."},{"key":"362_CR12","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1016\/j.exphem.2019.06.407","volume":"76","author":"A Mo","year":"2019","unstructured":"Mo, A. et al. Loss of FBXO11 functions drives acute myeloid leukemia. Exp. Hematol. 76, 3097 (2019). Abstract.","journal-title":"Exp. Hematol."},{"key":"362_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nm.4127","volume":"22","author":"J Fang","year":"2016","unstructured":"Fang, J. et al. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes. Nat. Med. 22, 727\u2013734 (2016).","journal-title":"Nat. Med."},{"key":"362_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"362_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-16193-9","volume":"7","author":"PN Spahn","year":"2017","unstructured":"Spahn, P. N. et al. PinAPL-Py: a comprehensive web-application for the analysis of CRISPR\/Cas9 screens. Sci. Rep. 7, 1\u20138 (2017).","journal-title":"Sci. Rep."},{"key":"362_CR16","doi-asserted-by":"crossref","unstructured":"Dwivedi P., et al. SWATH\u2010proteomics of ibrutinib\u2019s action in myeloid leukemia initiating mutated G\u2010CSFR signaling. Proteom. Clin. Appl. 14, 1900144 (2020).","DOI":"10.1002\/prca.201900144"},{"key":"362_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2009","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2009).","journal-title":"Bioinformatics"},{"key":"362_CR18","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2015","unstructured":"Colaprico, A. et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 44, e71\u2013e71 (2015).","journal-title":"Nucleic Acids Res."},{"key":"362_CR19","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukaemia. Nature 562, 526\u2013531 (2018).","journal-title":"Nature"},{"key":"362_CR20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","volume":"27","author":"E Kim","year":"2015","unstructured":"Kim, E. et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27, 617\u2013630 (2015).","journal-title":"Cancer Cell"},{"key":"362_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64\u201369 (2011).","journal-title":"Nature"},{"key":"362_CR22","doi-asserted-by":"publisher","first-page":"D881","DOI":"10.1093\/nar\/gky1076","volume":"47","author":"FO Bagger","year":"2018","unstructured":"Bagger, F. O., Kinalis, S. & Rapin, N. BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles. Nucleic Acids Res. 47, D881\u2013D5 (2018).","journal-title":"Nucleic Acids Res."},{"key":"362_CR23","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/blood-2015-11-684357","volume":"128","author":"C Schneider","year":"2016","unstructured":"Schneider, C. et al. FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease. Blood 128, 660\u2013666 (2016).","journal-title":"Blood"},{"key":"362_CR24","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1182\/bloodadvances.2018023689","volume":"2","author":"GJ Roboz","year":"2018","unstructured":"Roboz, G. J. et al. Randomized trial of 10 days of decitabine \u00b1 bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv. 2, 3608\u20133617 (2018).","journal-title":"Blood Adv."},{"key":"362_CR25","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1200\/JCO.2012.45.2177","volume":"31","author":"EC Attar","year":"2013","unstructured":"Attar, E. C. et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J. Clin. Oncol. 31, 923\u2013929 (2013).","journal-title":"J. Clin. Oncol."},{"key":"362_CR26","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1074\/jbc.M609001200","volume":"282","author":"WM Abida","year":"2007","unstructured":"Abida, W. M., Nikolaev, A., Zhao, W., Zhang, W. & Gu, W. FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity. J. Biol. Chem. 282, 1797\u2013804 (2007).","journal-title":"J. Biol. Chem."},{"key":"362_CR27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447 (2017).","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00362-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00362-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00362-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:35:15Z","timestamp":1670250915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00362-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["362"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-00362-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"5 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S. declares stock ownership in Abbvie Inc. D.S. is on the scientific advisory board at Kurome Therapeutics. The remaining authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"98"}}